New HPV test may replace Pap smear for diagnosing cervical cancer: All about it
The US FDA has approved a new self-swab test to check for human papillomavirus (HPV) infection. It helps people collect their own samples in a private setting instead of the traditional Pap smear test.
A Pap smear test is needed to check for cervical cancer. During the test, the doctor gently scrapes cells from the cervix (the lower part of the uterus) using a small brush. These cells are then examined under a microscope to detect any abnormal changes that may indicate cancer.
This is the most common type of test to check for human papillomavirus (HPV), which causes various types of cancer, including cervical cancer.
However, the US Food and Drug Administration (FDA) has approved a new test that allows patients to collect their own samples in a private location.
This test was developed for people who feel uncomfortable with the pelvic exam (Pap smear) required for this procedure for a variety of reasons, including past negative experiences or personal and cultural beliefs.
Manufactured by medical technology company Becton, Dickinson and Company (BD), the test, called the BD OnClarity HPV Assay, will be available in many doctors’ offices and clinics in the US.
The manufacturers announced that they have begun shipping these self-swab kits to healthcare facilities, and that these will be available by the end of September.
The new self-swab test gives patients the option of taking their own sample, which is then sent to a lab for analysis. The results are given to the patient’s doctor, who will follow up with the patient.
HPV is the most common sexually transmitted infection in the US and can cause serious cancers, including cervical cancer. It is also one of the most common sexually transmitted infections in India.
BD believes this less invasive method will encourage more people, particularly those living in deprived areas, to get screened and help prevent cervical cancer.
According to Dr. Jeff Andrews, gynecologist and BD’s vice president of global medical affairs, “Self-collection is simple, private and easy to use, making it a game-changer for people who have avoided screening.”
In addition, another self-swab HPV test developed by Roche Holding AG was also approved by the US FDA in May, although it has not yet been released.
Australia’s National Cervical Screening Program also offers self-screening tests for cervical cancer.
